Generic Name and Formulations:
Lidocaine HCl (as monohydrate) 0.5mg/device; pwd for intradermal inj.
Indications for ZINGO:
To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.
Adults and Children:
<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.
Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Local anesthetic (amide-type).
Additive effects with other local anesthetics.
Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.
Single-use device (disposable, needle-free)—12
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Lithium Monotherapy Effective in Treating Bipolar Disorder in Children
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Computerized Training Programs for Schizophrenia Improve Cognitive Functioning
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Cost-Effective Telehealth Alternatives for Veterans With Depression
- Polygenic Risk Scores Could Aid in Identifying Bipolar Disorder, Schizophrenia
- Brief Impression Questionnaire Useful in Schizophrenia Diagnoses